Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.

<h4>Objective</h4>Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Scle...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Viktoria Papp, Mathias Due Buron, Volkert Siersma, Peter Vestergaard Rasmussen, Zsolt Illes, Matthias Kant, Claudia Hilt, Zsolt Mezei, Homayoun Roshanisefat, Tobias Sejbæk, Arkadiusz Weglewski, Janneke van Wingerden, Svend Sparre Geertsen, Stephan Bramow, Finn Sellebjerg, Melinda Magyari
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4c38c13ec9ce425b87933408ba9724f9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4c38c13ec9ce425b87933408ba9724f9
record_format	dspace
spelling	oai:doaj.org-article:4c38c13ec9ce425b87933408ba9724f92021-12-02T20:11:18ZReal-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.1932-620310.1371/journal.pone.0250820https://doaj.org/article/4c38c13ec9ce425b87933408ba9724f92021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0250820https://doaj.org/toc/1932-6203<h4>Objective</h4>Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013-2019.<h4>Methods</h4>This was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits.<h4>Results</h4>A total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naïve. Compared to previously treated patients, treatment-naïve patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve versus previously treated patients experienced a relapse during the follow-up (p<0.0001). Furthermore, 85% of the patients with available data were free of disability worsening at the end of follow-up.<h4>Conclusions</h4>Solid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity.Viktoria PappMathias Due BuronVolkert SiersmaPeter Vestergaard RasmussenZsolt IllesMatthias KantClaudia HiltZsolt MezeiHomayoun RoshanisefatTobias SejbækArkadiusz WeglewskiJanneke van WingerdenSvend Sparre GeertsenStephan BramowFinn SellebjergMelinda MagyariPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 5, p e0250820 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Viktoria Papp Mathias Due Buron Volkert Siersma Peter Vestergaard Rasmussen Zsolt Illes Matthias Kant Claudia Hilt Zsolt Mezei Homayoun Roshanisefat Tobias Sejbæk Arkadiusz Weglewski Janneke van Wingerden Svend Sparre Geertsen Stephan Bramow Finn Sellebjerg Melinda Magyari Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
description	<h4>Objective</h4>Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013-2019.<h4>Methods</h4>This was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits.<h4>Results</h4>A total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naïve. Compared to previously treated patients, treatment-naïve patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve versus previously treated patients experienced a relapse during the follow-up (p<0.0001). Furthermore, 85% of the patients with available data were free of disability worsening at the end of follow-up.<h4>Conclusions</h4>Solid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity.
format	article
author	Viktoria Papp Mathias Due Buron Volkert Siersma Peter Vestergaard Rasmussen Zsolt Illes Matthias Kant Claudia Hilt Zsolt Mezei Homayoun Roshanisefat Tobias Sejbæk Arkadiusz Weglewski Janneke van Wingerden Svend Sparre Geertsen Stephan Bramow Finn Sellebjerg Melinda Magyari
author_facet	Viktoria Papp Mathias Due Buron Volkert Siersma Peter Vestergaard Rasmussen Zsolt Illes Matthias Kant Claudia Hilt Zsolt Mezei Homayoun Roshanisefat Tobias Sejbæk Arkadiusz Weglewski Janneke van Wingerden Svend Sparre Geertsen Stephan Bramow Finn Sellebjerg Melinda Magyari
author_sort	Viktoria Papp
title	Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
title_short	Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
title_full	Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
title_fullStr	Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
title_full_unstemmed	Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
title_sort	real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in the danish multiple sclerosis registry.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/4c38c13ec9ce425b87933408ba9724f9
work_keys_str_mv	AT viktoriapapp realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT mathiasdueburon realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT volkertsiersma realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT petervestergaardrasmussen realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT zsoltilles realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT matthiaskant realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT claudiahilt realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT zsoltmezei realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT homayounroshanisefat realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT tobiassejbæk realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT arkadiuszweglewski realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT jannekevanwingerden realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT svendsparregeertsen realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT stephanbramow realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT finnsellebjerg realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry AT melindamagyari realworldoutcomesforacompletenationwidecohortofmorethan3200teriflunomidetreatedmultiplesclerosispatientsinthedanishmultiplesclerosisregistry
_version_	1718374882229616640

Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.

Ejemplares similares